降压治疗与痴呆或认知障碍风险:系统综述与荟萃分析
结果显示,与对照组相比,降压治疗显著降低痴呆或认知障碍风险(OR 0.93,95%CI 0.88-0.98)及认知下降风险(OR 0.93,95%CI 0.88-0.99),但对认知测试评分变化无显著关联。
要点
- 降压治疗与痴呆或认知障碍风险降低显著相关(OR 0.93)。
- 降压治疗也与认知下降风险降低显著相关(OR 0.93)。
- 降压治疗对认知测试评分变化无显著影响。
核心结论
- 与对照组相比,使用降压药物降低血压与痴呆或认知障碍发生风险降低显著相关。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE和CENTRAL数据库自建库至2019年12月31日的随机临床试验。
主要发现
- 在平均随访4.1年中,降压治疗组痴呆或认知障碍发生率为7.0%,对照组为7.5%;OR 0.93(95%CI 0.88-0.98),绝对风险降低0.39%(95%CI 0.09%-0.68%),I2=0.0%。
- 在平均随访4.1年中,降压治疗组认知下降发生率为20.2%,对照组为21.1%;OR 0.93(95%CI 0.88-0.99),绝对风险降低0.71%(95%CI 0.19%-1.2%),I2=36.1%。
- 降压治疗与认知测试评分变化无显著关联。
临床怎么用
- 对于符合试验纳入标准的人群,使用降压药物降低血压可能有助于降低痴呆或认知障碍风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The benefit of blood pressure lowering for the prevention of dementia or cognitive impairment is unclear. OBJECTIVE: To determine the association of blood pressure lowering with dementia or cognitive impairment. DATA SOURCES AND STUDY SELECTION: Search of PubMed, EMBASE, and CENTRAL for randomized clinical trials published from database inception through December 31, 2019, that evaluated the association of blood pressure lowering on cognitive outcomes. The control groups consisted of either placebo, alternative antihypertensive agents, or higher blood pressure targets. DATA EXTRACTION AND SYNTHESIS: Data were screened and extracted independently by 2 authors. Random-effects meta-analysis models were used to report pooled treatment effects and CIs. MAIN OUTCOMES AND MEASURES: The primary outcome was dementia or cognitive impairment. The secondary outcomes were cognitive decline and changes in cognitive test scores. RESULTS: Fourteen randomized clinical trials were eligible for inclusion (96 158 participants), of which 12 reported the incidence of dementia (or composite of dementia and cognitive impairment [3 trials]) on follow-up and were included in the primary meta-analysis, 8 reported cognitive decline, and 8 reported changes in cognitive test scores. The mean (SD) age of trial participants was 69 (5.4) years and 40 617 (42.2%) were women. The mean systolic baseline blood pressure was 154 (14.9) mm Hg and the mean diastolic blood pressure was 83.3 (9.9) mm Hg. The mean duration of follow-up was 49.2 months. Blood pressure lowering with antihypertensive agents compared with control was significantly associated with a reduced risk of dementia or cognitive impairment (12 trials; 92 135 participants) (7.0% vs 7.5% of patients over a mean trial follow-up of 4.1 years; odds ratio [OR], 0.93 [95% CI, 0.88-0.98]; absolute risk reduction, 0.39% [95% CI, 0.09%-0.68%]; I2 = 0.0%) and cognitive decline (8 trials) (20.2% vs 21.1% of participants over a mean trial follow-up of 4.1 years; OR, 0.93 [95% CI, 0.88-0.99]; absolute risk reduction, 0.71% [95% CI, 0.19%-1.2%]; I2 = 36.1%). Blood pressure lowering was not significantly associated with a change in cognitive test scores. CONCLUSIONS AND RELEVANCE: In this meta-analysis of randomized clinical trials, blood pressure lowering with antihypertensive agents compared with control was significantly associated with a lower risk of incident dementia or cognitive impairment.
引用
- Hughes D, Judge C, Murphy R, et al. Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA. 2020. PMID: 32427305. doi:10.1001/jama.2020.4249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。